EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA

Evangelos Terpos iD, Ioannis Ntanasis-Stathopoulos iD, Maria Gavriatopoulou iD, Eirini Katodritou iD, Evdoxia Hatjiharissi, Panagiotis Malandrakis, Evgenia Verrou, Stavros Golfinopoulos, Magdalini Migkou, Kyriaki Manousou, Sosana Delimpasi iD, Argiris Symeonidis iD und 2 weitere

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27206 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Evangelos Terpos und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. Hauptthemen laut MEDLINE: Thalidomide, Multiple Myeloma, Antibodies, Monoclonal, Boron Compounds. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Pharmaceutica, Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of lenalidomide in frontline therapy for patients with newly diagnosed multiple myeloma (MM) has increased the number of those who become refractory to lenalidomide at second line. In this context, we assessed the efficacy of daratumumab in combination with ixazomib and dexamethasone (Dara‐Ixa‐dex) in the prospective phase 2 study DARIA. Eligible patients had relapsed/refractory MM (RRMM) after one prior line with a lenalidomide‐based regimen. The primary endpoint was overall response rate (ORR). Secondary endpoints included survival outcomes, safety and changes in biomarkers of bone metabolism. Overall, 50 patients were enrolled (median age 69 years, 56% males). 32 (64%) patients were refractory to lenalidomide, and 17 (34%) had undergone autologous transplant. The ORR was 64% ( n = 32); whereas 17 (34%) had a very good partial response or better. The median time to first response was 1.0 month. After a median follow‐up of 23.4 months, the median PFS and OS were 8.1 and 39.2 months, respectively. Furthermore, significant changes in markers of bone metabolism became evident as early as at 6 months on treatment. Regarding safety, 21 (42%) patients had ≥1 grade 3/4 adverse event (AE); the most common was thrombocytopenia ( n = 9, 18%). 14 (28%) patients had ≥1 serious AE (SAE), the most common being acute kidney injury and pneumonia ( n = 2, each). Four patients died due to infections. In conclusion, second‐line treatment with Dara‐Ixa‐dex in patients with RRMM pre‐treated with a lenalidomide‐based regimen resulted in rapid responses along with a favorable effect on bone metabolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThalidomideMultiple MyelomaAntibodies, MonoclonalBoron CompoundsMaleHumansAgedFemaleLenalidomideProspective StudiesDexamethasoneAntineoplastic Combined Chemotherapy ProtocolsGlycine

Substanzen

LenalidomideixazomibdaratumumabThalidomideDexamethasoneAntibodies, MonoclonalBoron CompoundsGlycine

Autor:innen und Institutionen

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
  • Department of Hematology, Theagenio Cancer Hospital, Thessaloniki, Greece.
  • First Department of Internal Medicine, Division of Haematology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Health Data Specialists, Dublin, Ireland.
  • Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece.
  • Hematology Division, Department of Internal Medicine, University of Patras Medical School, Patras, Greece.

ORCID-Profile: Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Eirini Katodritou, Sosana Delimpasi, Argiris Symeonidis, Efstathios Kastritis, Meletios A Dimopoulos

Förderung

  • Janssen Pharmaceutica
  • Takeda Pharmaceutical Company

Zitieren

APA

Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Katodritou, E., Hatjiharissi, E., Malandrakis, P., Verrou, E., Golfinopoulos, S., Migkou, M., Manousou, K., Delimpasi, S., Symeonidis, A., Kastritis, E., & Dimopoulos, M. A. (2024). Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA. American Journal of Hematology. https://doi.org/10.1002/ajh.27206

Vancouver

Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Katodritou E, Hatjiharissi E, Malandrakis P, et al. Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA. American Journal of Hematology. 2024. doi:10.1002/ajh.27206

BibTeX
@article{Terpos2024,
  author = {Terpos, Evangelos and Ntanasis-Stathopoulos, Ioannis and Gavriatopoulou, Maria and Katodritou, Eirini and Hatjiharissi, Evdoxia and Malandrakis, Panagiotis and Verrou, Evgenia and Golfinopoulos, Stavros and Migkou, Magdalini and Manousou, Kyriaki and Delimpasi, Sosana and Symeonidis, Argiris and Kastritis, Efstathios and Dimopoulos, Meletios A},
  title = {Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27206}
}
Kostenlos starten →